Analysts at Oppenheimer on Tuesday upgraded their rating on General Electric Co. stock to the equivalent of buy, reflecting "strong" momentum for its aviation business, "consistent and broad-based profitability" for its power business, and the fact that the health-care unit is on track for a spinoff. The analysts also raised their price target on the stock to $104, representing an upside of around 22% from Tuesday prices. GE last week said its board officially approved the GE HealthCare spinoff, with the unit becoming a corporation to be named GE HealthCare Technologies Inc. The company is expected to begin trading on the Nasdaq on Jan. 4. Shares of GE have lost about 11% so far this year, compared with losses of around 17% for the S&P 500 index.
Any recommendation, opinion or advice regarding securities or markets contained in such material does not reflect the views of TD Ameritrade, and TD Ameritrade does not verify any information included in such material.